Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer

Sławomir Ławicki, M.D.¹, Edyta Katarzyna Głażewska, M.S.², Monika Sobolewska, M.S.¹, Grażyna Ewa Będkowska, Ph.D.³, and Maciej Szmitkowski, M.D.¹

Department of Biochemical Diagnostics¹, Laboratory of Esthetic Medicine², Department of Haematological Diagnostics³, Medical University, Białystok, Poland

Background: Macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase-9 (MMP-9), and its specific tissue inhibitor - tissue inhibitor of metalloproteinases-1 (TIMP-1) may play an important role in the pathogenesis and spread of cancer. We investigated the plasma levels of M-CSF, MMP-9, and TIMP-1 in comparison with a commonly accepted tumor marker CA 15-3 in breast cancer patients and in control groups.

Methods: The cohort included 110 breast cancer patients in groups at stages I-IV. The control group consisted of 50 healthy volunteers and 50 benign tumor patients. Plasma levels of M-CSF, MMP-9, and TIMP-1 were determined by using ELISA, while CA 15-3 concentrations were determined by using chemiluminescent microparticle immunoassay (CMIA).

Results: The results showed significant differences in concentrations of the analyzed parameters and in levels of CA 15-3 between the groups of breast cancer patients and the two control groups. Diagnosis using these markers was equal to that using CA 15-3 in terms of sensitivity, predictive values of positive and negative test results (PPV, NPV) and area under the ROC curve (AUC) in the studied groups. The diagnostic specificities of MMP-9, TIMP-1, M-CSF, and CA 15-3 showed equally high values (95%). The combined use of all tested parameters with CA 15-3 resulted in increased sensitivity, NPV, and AUC, especially in the combination of M-CSF with tumor markers (76%, 64%, and 0.8653).

Conclusions: These findings suggest the tested parameters are useful in the diagnosis of breast cancer patients (except stage I), when combined with CA 15-3.

Key Words: Breast cancer, CA 15-3, M-CSF, MMP-9, TIMP-1

INTRODUCTION

Breast cancer is the most common malignant disease among women. In 2014 in the United States alone, 232,670 women were diagnosed as having this type of cancer, and 40,000 of them died [1]. Breast tumors can appear at any age but the incidence increases drastically after the age of 50, in connection with hormonal changes [2].

The most effective way to prevent mortality caused by breast cancer is early diagnosis. Biochemical detection of this cancer is based on the determination of markers such as CA 15-3, CEA, and CA 27.29 [3]. However, these are still neither fully specific nor sensitive; hence the researchers attempt to find the biomarkers whose levels would correlate with the presence and
stage of breast cancer. We assumed that these factors might include matrix metalloproteinase (MMP), tissue inhibitors of matrix metalloproteinase (TIMPs), and cytokines, for example macrophage colony-stimulating factor (M-CSF). The diagnostic role of the analyzed parameters will involve determination of breast tumor stage based on the following relationship: the more advanced tumor stage, the higher the concentration of these substances.

MMPs form a large group of enzymes responsible for the remodeling of the extracellular matrix (ECM) in tumor invasion [4]. One of them – MMP-9 – also known as a gelatinase B, plays an important role in cancer growth and invasion with its unique ability to destroy collagen type IV and other ECM components. Furthermore, overexpression of this factor correlates with poor prognosis and patient survival [5].

TIMPs are natural inhibitors of MMPs. Only four proteins are included in this group [6]. TIMP-1 can be detected in a variety of body fluids and tissues. This factor stimulates cancer invasion by apoptosis inhibition, promotion of tumor cell growth, and regulation of angiogenesis [7]. The relationship between high levels of TIMP-1 and poor prognosis of breast tumor patients had been confirmed [8].

Previous studies revealed an autologous synthesis of M-CSF in various human cancer cell lines in vitro and by tumors in vivo. This glycoprotein, which belongs to the group of hematopoietic growth factors (HGFs), is responsible for monocyte production and function; yet in pathological conditions, it stimulates cancer cell growth [9].

The aim of this study was to evaluate the plasma levels of MMP-9, TIMP-1, M-CSF, and CA 15-3 (comparative marker) in breast tumor patients in respect to two control groups: benign breast tumor patients and healthy subjects. The data obtained in this work may be helpful in both the determination of the usefulness of the analyzed parameters (separately and together) in diagnosis of breast cancer and the differentiation of its subtypes.

**METHODS**

1. **Patients**

Table 1 shows the tested groups. The study included 110 breast cancer patients whose conditions were diagnosed by the Oncology Group and treated in the Department of Oncology, Medical University, Białystok, Poland, between 2013 and 2015. Tumor classification and staging were carried out in accordance with the International Union Against Cancer Tumor-Node-Metastasis (UICC-TNM) classifications [10]. The breast cancer histopathology was established in all cases by tissue biopsy of mammary tumor or based on tumor cancer tissues collected during surgery (all patients with adenocarcinoma ductale). Pretreatment staging procedures included physical and blood examinations, mammography, mammary ultrasound scanning, breast core biopsies, and chest X-ray. In addition, radioisotopic bone scans, examination of bone marrow aspirates, and brain or chest computerized tomography (CT) scans were performed when necessary. None of the patients had received chemo- or radiotherapy before blood sample collection.

The control groups included 50 patients with benign breast tumors and 50 healthy untreated women who had undergone mammary gland examination performed by a gynecologist prior to blood collection. Moreover, mammary ultrasound scanning was performed when necessary. The benign breast tumor histopathology was established in all cases with the use of tissue bi-

| Study group | N of patients |
|-------------|---------------|
| Breast cancer patients | Adenocarcinoma ductale |
| Type | N of patients |
| - Premenopausal | 110 |
| - Postmenopausal | 54 (35-76) |
| Median age (range) | 22 |
| Tumor stage | 10 |
| - IIA-T,N,Mb | 10 |
| - IIIB-T,N,Mb | 14 |
| Menopausal status: | 9 |
| - Premenopausal | 7 |
| - Postmenopausal | 7 |
| Benign breast tumor | IV (metastases) |
| Type | 23 |
| - Adenoma papilloma | 52 |
| Intraductale | 58 |
| Fibroadenoma | 43 (23-71) |
| Mastopatia | 16 |
| Median age (range) | 34 |
| Menopausal status: | 11 |
| - Premenopausal | 4 |
| - Postmenopausal | 30 |
| Healthy subjects | 50 |
| Menopausal status: | 41 (20-72) |
| - Premenopausal | 20 |
| - Postmenopausal | 30 |

---

### Table 1. Characteristics of breast cancer patients and control groups: benign breast tumor patients and healthy subjects

1. **Patients**

Table 1 shows the tested groups. The study included 110 breast cancer patients whose conditions were diagnosed by the Oncology Group and treated in the Department of Oncology, Medical University, Białystok, Poland, between 2013 and 2015. Tumor classification and staging were carried out in accordance with the International Union Against Cancer Tumor-Node-Metastasis (UICC-TNM) classifications [10]. The breast cancer histopathology was established in all cases by tissue biopsy of mammary tumor or based on tumor cancer tissues collected during surgery (all patients with adenocarcinoma ductale). Pretreatment staging procedures included physical and blood examinations, mammography, mammary ultrasound scanning, breast core biopsies, and chest X-ray. In addition, radioisotopic bone scans, examination of bone marrow aspirates, and brain or chest computerized tomography (CT) scans were performed when necessary. None of the patients had received chemo- or radiotherapy before blood sample collection.

The control groups included 50 patients with benign breast tumors and 50 healthy untreated women who had undergone mammary gland examination performed by a gynecologist prior to blood collection. Moreover, mammary ultrasound scanning was performed when necessary. The benign breast tumor histopathology was established in all cases with the use of tissue bi-

---

### Table 1. Characteristics of breast cancer patients and control groups: benign breast tumor patients and healthy subjects

| Study group | N of patients |
|-------------|---------------|
| Breast cancer patients | Adenocarcinoma ductale |
| Type | N of patients |
| - Premenopausal | 110 |
| - Postmenopausal | 54 (35-76) |
| Median age (range) | 22 |
| Tumor stage | 10 |
| - IIA-T,N,Mb | 10 |
| - IIIB-T,N,Mb | 14 |
| Menopausal status: | 9 |
| - Premenopausal | 7 |
| - Postmenopausal | 7 |
| Benign breast tumor | IV (metastases) |
| Type | 23 |
| - Adenoma papilloma | 52 |
| Intraductale | 58 |
| Fibroadenoma | 43 (23-71) |
| Mastopatia | 16 |
| Median age (range) | 34 |
| Menopausal status: | 11 |
| - Premenopausal | 4 |
| - Postmenopausal | 30 |
| Healthy subjects | 50 |
| Menopausal status: | 41 (20-72) |
| - Premenopausal | 20 |
| - Postmenopausal | 30 |
opsy of mammmary tumor or after surgery.

The study was approved by the local Ethics Committee in Medical University in Białystok no R-I-002/239/2014/. All the patients gave their informed written consent for the examination.

2. Biochemical analyses

Venous blood samples were collected from each patient into a heparin sodium tube, centrifuged for 15 min at 1,000g to obtain plasma samples, and stored at -85°C until assayed. The tested cytokines (MMP-9, TIMP-1, and M-CSF) were measured by using ELISA (Quantikine Human HGFs Immunoassay, R&D systems, Minneapolis, MN, USA), according to the manufacturer’s protocols. Duplicate samples were assessed for each patient.

The intra-assay CV of MMP-9 is reported to be 1.9% at a mean concentration of 2.04 ng/mL, SD=0.039; TIMP-1-3.9% at a mean concentration of 1.27 ng/mL while SD=0.05; M-CSF-3.4% at mean concentration of 227 pg/mL, SD=7.7. The inter-assay CV of MMP-9 amounted to 7.8% at a mean concentration of 2.35 ng/mL, SD=0.184; TIMP-1-3.9% at a mean concentration of 1.28 ng/mL while SD=0.05; and M-CSF-3.1% at mean concentration of 232 pg/mL, SD=7.3. The assay showed no significant cross-reactivity or interference with numerous human cytokines and other growth factors.

The plasma concentrations of CA 15-3 were measured with chemiluminescent microparticle immunoassay (CMIA) (Abbott, Abbott Park, IL, USA). The intra-assay CV for CA 15-3 is reported to be 2.2% at mean concentration of 27.0 U/mL, SD=0.6 while the inter-assay CV for CA 15-3 is reported to be 2.6% at mean concentration of 27.0 U/mL, SD=0.7.

The value of intra- and inter-assay CVs were calculated by the manufacturers and enclosed in the reagent kits.

3. Statistical analysis

Statistical analysis was performed by using STATISTICA 8.0 Pl (StatSoft, Tulsa, OK, USA). A preliminary statistical analysis (Chi-square test) revealed that the cytokine and tumor marker levels did not follow normal distribution. Consequently, the Mann-Whitney U test was used for statistical analysis between cancer patients and control groups. Additionally, statistical analysis between the groups with different stages of breast cancer was performed by using the Kruskal-Wallis test and a multivariate analysis of various data by the post-hoc Dwass-Steele-Crichlow-Flinger test. The data were presented as a median and a range [11].

Diagnostic sensitivity, specificity, and the predictive values of positive and negative test results (PPV, NPV) were calculated by using the following cut-off value: 95th percentile from the control group (calculated from healthy blood donors). This value for each of the substances was as follows: MMP-9-382.00 ng/mL; TIMP-1-119.22 ng/mL; M-CSF-396.94 pg/mL; and CA 15-3-20.85 U/mL. The construction of the ROC curves was performed using GraphRoc program for Windows (Windows,Royal, AR, USA) and the areas under the ROC curve (AUC) were calculated.

In the analyses of both diagnostic performance (sensitivity, specificity, PPV, and NPV) and ROC curve, only healthy subjects were used as a control group.

RESULTS

Table 2 presents the median and the range of plasma levels of the investigated parameters and CA 15-3 in tested groups. The median values for MMP-9 (286.00 ng/mL) and M-CSF (437.05 pg/mL), similar to those of commonly accepted tumor marker CA 15-3 (26.90 U/mL) in all breast cancer patients (stages I-IV) were significantly higher compared with the values in healthy subjects (181.00 ng/mL; 281.20 pg/mL; 15.20 U/mL, respectively) (P<0.001). Furthermore, the median level of TIMP-1 in BC total group (155.74 ng/mL) was significantly higher than that in the benign breast tumor group (74.75 ng/mL). We also noticed significantly higher concentrations of M-CSF and CA 15-3 at stage III or IV of cancer compared with stage I or II (M-CSF: I vs. III P<0.001, I vs. IV P<0.001 and II vs. III P=0.005, II vs. IV P=0.001; CA 15-3: I vs. III P=0.001, I vs. IV P<0.001 and II vs. III P=0.023, II vs. IV P=0.001). Furthermore, we detected significantly higher plasma levels of TIMP-1 in the comparison of stage III to stage I (P=0.018) and to stage II (P=0.042).

Additionally, we observed significantly higher concentrations of CA 15-3 in all the analyzed groups at all stages of breast cancer (with the exception of stage I) in comparison with healthy women (P values were: 0.004 at stage I and below 0.001 at stages II and III).

Moreover, M-CSF, TIMP-1, and CA 15-3 concentrations showed a statistical difference between the two control groups (Table 2).

Table 3 shows the diagnostic criteria: sensitivity, specificity, PPV, and NPV in breast cancer patients. The sensitivity of the tested parameters in the total cancer group was higher for M-CSF (57%) than for MMP-9 (38%) and TIMP-1 (18%), and slightly lower than for CA 15-3 (64%). The combined use of tested factors with CA 15-3 resulted in an increase in sensitivity. A maximum value for the BC total group was obtained for the combination of four studied parameters (84%). Among all tested factors, CA 15-3 showed the highest sensitivity at almost
every stage of cancer (with the exception of stage III—equal to M-CSF—and stage IV— the highest value of M-CSF). The sensitivity of the analysis using the tested parameters distinctly rose with the increase in the stage of cancer (with the exception of MMP-9 and TIMP-1 at stage IV), in an identical manner to CA 15-3. The combined use of the analyzed factors and antigen CA 15-3 resulted in an increase in sensitivity at every stage of breast cancer. Higher values were obtained for the combination of MMP-9, TIMP-1, or M-CSF with CA 15-3 (stage III—97%, 87%, 97%, stage IV—87%, 87%, 96%; respectively). A maximum range was observed for the combination of all studied parameters at stage III and IV of breast cancer (100%).

The diagnostic specificity for M-CSF, MMP-9, TIMP-1, and CA 15-3 showed very high values (95% in all cases). The PPVs in the total group of breast cancer patients was the highest for M-CSF and CA 15-3 (97%) compared with MMP-9 (95%) and TIMP-1 (91%). The combined use of the tested parameters with CA 15-3 resulted in a decrease in the PPV range (Table 3).

The NPVs in the total group of breast cancer was repeatedly higher for CA 15-3 (48%) than for M-CSF (45%), MMP-9 (36%), and TIMP-1 (29%). The combined use of the tested factors and CA 15-3 resulted in an increase in the NPV in all cases, for example with M-CSF—to 59%. A maximum range was obtained for the combination of CA 15-3, M-CSF, MMP-9, and TIMP-1-64%. The combined use of the analyzed parameters and CA 15-3 resulted in an increase in the NPV at every cancer stage. Maximum equal ranges (100%) were obtained for the combination of M-CSF, MMP-9, TIMP-1, and CA 15-3 at stage III and IV of BC (Table 3).

The relationship between the diagnostic sensitivity and specificity is illustrated by the ROC curve. The AUC indicates the clinical usefulness of a tumor marker and its diagnostic power. We noticed that the M-CSF AUC (0.7955) in the total breast cancer group was larger than the area of MMP-9 (0.6827) and TIMP-1 (0.6250) and slightly lower than the AUC of CA 15-3 (0.8548). In case of MMP-9 and M-CSF, the AUC was significantly larger in comparison with AUC=0.5, which is similar to the case of CA 15-3 (borderline of the diagnostic usefulness of the test) (P<0.001; in all cases). The combined analysis of AUC tested parameters with CA 15-3 resulted in an increase in the AUCs for MMP-9, TIMP-1, and M-CSF with CA 15-3 were significantly larger in comparison with AUC=0.5 (Fig. 1) (Table 4).

Table 2. Plasma levels of tested parameters and CA 15-3 in patients with breast cancer and in control groups

| Groups tested | MMP-9 (ng/mL) | TIMP-1 (ng/mL) | M-CSF (pg/mL) | CA 15-3 (U/mL) |
|---------------|---------------|---------------|---------------|---------------|
| Breast cancer |               |               |               |               |
| Stage I       | 267.8         | 98.825        | 299.975       | 19.95         |
| Median range  | 46.80-736.90  | 44.44-334.00  | 134.50-476.40 | 7.10-34.20*   |
| Stage II      | 274           | 130.195       | 347.65        | 23.4          |
|               | 93.60-830.12* | 33.08-346.85* | 213.70-805.80* | 7.80-38*      |
| Stage III     | 360           | 198.2         | 652.05        | 34            |
|               | 50.968-840.00 | 77.55-440.66  | 308.90-1,791.05* | 17.50-167.50* |
| Stage IV      | 273           | 162.23        | 692.15        | 74.4          |
|               | 52.80-800.00* | 4.58-438.52*  | 248.00-1,527.175* | 18.50-250.00* |
| Total group   | 286           | 155.74        | 437.05        | 26.9          |
|               | 46.80-840.00  | 4.58-440.66*  | 134.5-1,791.05* | 7.10-250.00*  |
| Control groups|               |               |               |               |
| Benign breast tumor | 209.2       | 74.75        | 448.1        | 25.2          |
| Median range  | 36.00-840.00  | 6.71-157.78   | 144.00-1,425.00 | 12.10-48.30 |
| Healthy subjects | 181          | 123.74       | 281.2        | 15.2          |
|               | 65.60-420.00  | 33.08-331.64  | 162.15-455.50 | 6.90-27.20   |

*Statistically significant when compared breast cancer patients with healthy subjects (P<0.05); †Statistically significant when compared breast cancer patients with benign breast tumor group (P<0.05); ‡Statistically significant when compared breast cancer patients stage III or IV with breast cancer patients stage I or II (P<0.05); §Statistically significant when compared benign breast tumor patients with healthy subjects (P<0.05).

Abbreviations: MMP-9, matrix metalloproteinase-9; TIMP-1, tissue inhibitor of metalloproteinases-1; M-CSF, macrophage colony–stimulating factor.
Table 3. Diagnostic criteria of tested parameters and in combined analysis with CA 15-3 in breast cancer patients

| Parameters tested | Diagnostic criteria (%) | Breast cancer |
|-------------------|-------------------------|---------------|
|                   | Stage I | Stage II | Stage III | Stage IV | Total group |
| MMP-9             |         |          |           |          |             |
| Sensitivity       | 27      | 35       | 45        | 43       | 38          |
| Specificity       | 95      | 95       | 95        | 95       | 95          |
| PPV               | 75      | 86       | 88        | 83       | 95          |
| NPV               | 70      | 75       | 69        | 75       | 36          |
| TIMP-1            |         |          |           |          |             |
| Sensitivity       | 9       | 8        | 35        | 17       | 18          |
| Specificity       | 95      | 95       | 95        | 95       | 95          |
| PPV               | 50      | 60       | 85        | 67       | 91          |
| NPV               | 66      | 55       | 66        | 64       | 29          |
| M-CSF             |         |          |           |          |             |
| Sensitivity       | 18      | 38       | 84        | 87       | 57          |
| Specificity       | 95      | 95       | 95        | 95       | 95          |
| PPV               | 67      | 87       | 93        | 91       | 97          |
| NPV               | 68      | 64       | 88        | 93       | 45          |
| CA 15-3           |         |          |           |          |             |
| Sensitivity       | 32      | 50       | 84        | 83       | 63          |
| Specificity       | 95      | 95       | 95        | 95       | 95          |
| PPV               | 78      | 89       | 93        | 90       | 97          |
| NPV               | 72      | 81       | 88        | 90       | 48          |
| MMP-9+            |         |          |           |          |             |
| Sensitivity       | 41      | 65       | 97        | 87       | 74          |
| CA 15-3           |         |          |           |          |             |
| Specificity       | 90      | 90       | 90        | 90       | 90          |
| PPV               | 69      | 85       | 88        | 83       | 95          |
| NPV               | 73      | 75       | 97        | 92       | 55          |
| TIMP-1+           |         |          |           |          |             |
| Sensitivity       | 36      | 50       | 87        | 87       | 65          |
| CA 15-3           |         |          |           |          |             |
| Specificity       | 90      | 90       | 90        | 90       | 90          |
| PPV               | 67      | 81       | 87        | 83       | 95          |
| NPV               | 72      | 68       | 90        | 92       | 49          |
| M-CSF+            |         |          |           |          |             |
| Sensitivity       | 45      | 68       | 97        | 96       | 77          |
| CA 15-3           |         |          |           |          |             |
| Specificity       | 90      | 90       | 90        | 90       | 90          |
| PPV               | 71      | 85       | 88        | 85       | 96          |
| NPV               | 75      | 77       | 97        | 97       | 59          |
| MMP-9+            |         |          |           |          |             |
| Sensitivity       | 55      | 76       | 100       | 100      | 84          |
| TIMP-1+           |         |          |           |          |             |
| Specificity       | 83      | 83       | 83        | 83       | 83          |
| M-CSF+            |         |          |           |          |             |
| PPV               | 60      | 76       | 79        | 74       | 92          |
| CA 15-3           |         |          |           |          |             |
| NPV               | 76      | 80       | 100       | 100      | 64          |

Table 4. Diagnostic criteria of the ROC curve for tested parameters and CA 15-3

| Parameters tested | ROC criteria in breast cancer total group |
|-------------------|------------------------------------------|
|                   | AUC | Sensitivity | 95% CI | P            |
| M-CSF             | 0.7955 | 0.0381 | 0.721-0.870 | <0.001 |
| MMP-9             | 0.6827 | 0.0511 | 0.582-0.783 | <0.001 |
| TIMP-1            | 0.6250 | 0.0574 | 0.513-0.738 | 0.0294 |
| CA 15-3           | 0.8548 | 0.0346 | 0.787-0.923 | <0.001 |
| MMP-9 + CA 15-3   | 0.8840 | 0.0287 | 0.828-0.940 | <0.001 |
| MMP-9 + TIMP-1    | 0.8851 | 0.0289 | 0.829-0.942 | <0.001 |
| M-CSF + TIMP-1 +  | 0.8547 | 0.0346 | 0.878-0.922 | <0.001 |
| M-CSF + MMP-9 +   | 0.9125 | 0.0241 | 0.865-0.960 | <0.001 |
| TIMP-1 + CA 15-3  |       |        |         |             |

DISCUSSION

The group of HGFs is composed of cytokines such as stem cell factor (SCF), interleukin 3 (IL-3), granulocyte-macrophage-col-ony-stimulating factor (GM-CSF), granulocyte-colony stimulating factor (G-CSF), and M-CSF. Their main function is regulation of hematopoietic progenitor cell growth and differentiation. Furthermore, HGFs have the ability to stimulate the proliferation of non-hematopoietic cells in vitro, for instance cancer cells [12]. Significant plasma overexpression of M-CSF was detected in patients suffering from many types of tumors, for instance endometrial [13], ovarian [14], or breast tumors [15]. Moreover, scientists who examined this factor demonstrated that M-CSF is a good candidate as a marker of pancreatic tumor [16] or non-

Fig. 1. Diagnostic criteria of ROC curve for tested parameters and in combination with CA 15-3 in total breast cancer group. Abbreviations: MMP-9, matrix metalloproteinase-9; TIMP-1, tissue inhibitor of metalloproteinases-1; M-CSF, macrophage colony-stimulating factor.
small-cell lung cancer [17]. McDermont et al. [18] found that serum levels of this marker were elevated in breast cancer patients but the highest concentrations of M-CSF were detected by Kaciński [19] in the ascites and pleural effusion of the patients in the advanced stages of this cancer. The high grade and poor prognosis correlated with elevated levels of M-CSF [20].

MMPs and TIMPs play a crucial role in ECM and basement membrane homeostasis [21]. Giannelli et al. [22] proved that in physiological conditions, the MMP: TIMP ratio is highly regulated. The imbalance between concentrations and activities of those factors may lead to the disturbances in the production and degradation of ECM components. They also demonstrated that the MMP and TIMP dysfunction might lead to faster invasion and metastasis of the cancer. Moreover, Jinga et al. [23] affirmed that high ratios of MMP-9: TIMP-1 signify strong proteolytic ability of MMPs (especially gelatinases) in malignant tumors. The correlation between the levels of MMP-9 and TIMP-1 and breast tumor sizes was not previously confirmed [24].

According to our research, plasma concentrations of MMP-9, M-CSF, and CA 15-3 were significantly higher in the whole breast cancer group than in healthy subjects. The same observations on MMP-9 were reported previously [23-25]. The overexpression of M-CSF in similar groups was confirmed by Kaciński [19]. We also found comparable data in our previous studies [26, 27].

Contrary to the other parameters analyzed in this study, there was no difference between TIMP-1 levels in healthy subjects and breast cancer patients. According to other researchers, the concentrations of TIMP-1 were either significantly lower [28] or significantly higher [29] in carcinomas versus fibroadenomas. Interestingly, the levels of TIMP-1, M-CSF, and CA 15-3 were significantly higher in total breast cancer patients than in benign breast tumor cases. These observations about M-CSF and CA 15-3 are in accordance with both the data found in our previous studies, in which we analyzed a smaller benign breast cancer group [14] and the study by Wu et al. [24]. Concurrently, Jinga et al. [23] found no statistical differences between TIMP-1 serum levels in benign and malignant cases.

In this work we found that MMP-9, TIMP-1, and M-CSF present high levels at stage III and IV. The highest concentrations of these factors are probably the consequence of a higher mass of cancer cells. This is the further argument for our theory that the analyzed factors can play a prognostic role on the basis of following relationship: the more advanced tumor stage, the higher the concentration of the substance.

In the present study, the diagnostic sensitivity of M-CSF in total breast cancer patient group (57%) was higher than that of MMP-9 (38%) and TIMP-1 (18%) and slightly lower than that of CA 15-3 (63%). In our previous studies on breast cancer, M-CSF showed a higher sensitivity than CA 15-3 [25, 26]. Concurrently, MMP-9 presented the highest sensitivity at stage I of BC (27%), but still slightly lower than that of CA 15-3 (32%).

Moreover, current findings, similarly to our former works, proved that the combination of the commonly accepted tumor markers and the factors which may be useful in early detection of breast cancer significantly increases the pre-operative diagnostic sensitivity.

In this study, M-CSF had the highest predictive values of all tested factors, similar to that of CA 15-3, at every stage of cancer. The M-CSF diagnostic criteria are the highest for the group with stage IV cancer, which probably resulted from their vital role in the formation of both local and distant metastases [18].

The ROC curve illustrated by a specificity/sensitivity diagram is a crucial value describing all markers. The best cancer markers are characterized by the largest AUCs. In the present study, the AUC of M-CSF was the largest among the analyzed parameters, yet slightly lower than CA 15-3. Additionally, we detected significantly larger AUCs for M-CSF, MMP-9, TIMP-1, and CA 15-3 compared with AUC=0.5. Our data demonstrated that the diagnostic power of the analyzed parameters, in particular M-CSF in total breast cancer patients group, had a higher value than the diagnostic power of M-CSF in cervical cancer [12].

The examined factors are unsuitable for basic screening when considered separately. Their diagnostic usefulness is high in their combined analysis with a comparison tumor marker (in this case with CA 15-3); yet the greatest diagnostic value is observed when they are considered altogether as a new panel of biomarkers.

In conclusion, the obtained results suggest the usefulness of M-CSF, MMP-9, and TIMP-1 in the diagnostics of breast cancer except in stage I—yet only in combination with CA 15-3. Our findings seem to be ambiguous, although they are a promising step forward. The main limitation of the study was lack of significant differences in concentrations of analyzed factors between patients with stage I and healthy subjects. Therefore, further investigation will be necessary to clarify the utility of this new biomarker panel in clinical management.

Authors’ Disclosures of Potential Conflicts Of Interest

No potential conflicts of interest relevant to this article were reported.
REFERENCES

1. American Cancer Society. Cancer Facts & Figures 2014. Atlanta, GA: American Cancer Society, 2014-4.

2. Trichopoulos D, Adami HO, Ekblom A, Hsieh CC, Lagiou P. Early life events and conditions and breast cancer risk: from epidemiology to etiology. Int J Cancer 2008;122:481-5.

3. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312.

4. Fingleton B. Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci 2006;11:479-91.

5. Pellikainen JM, Ropponen KM, KatajaVV, Kellokoski UK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004;10:7621-8.

6. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. BiochimBiophysActa 2000;1477:267-83.

7. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1,-2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 1998;101:1478-87.

8. Talvensaari-Mattila A andTurpeenniemi-Hujanen T. High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma. Breast Cancer Res Treat 2005;95:29-34.

9. Lin EY, Gouon-Evans V, Nguyen AV, Pollard JW. The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J Mammary Gland BioiNeoplasia 2002;7:147-62.

10. Sobin LH, Gospodarowicz MK, et al. eds. TNM classification of malignant tumours. 7th ed. Chichester: John Wiley & Sons, 2011:181-3.

11. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.

12. Ławicki S, Będkowska GE, Gacuta-Szumarska E, Knapp P, Szmitkowski M. Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients. Folia HistochemCytobiol 2012;50:213-9.

13. Ławicki S, Będkowska GE, Gacuta-Szumarska E, Cyżygier M, Szmitkowski M. The plasma levels and diagnostics utility of selected hematopoietic growth factors in endometrial cancer patients and with myoma uteri. Pol MerkurLekarski 2010;28:354-8.

14. Ławicki S, Gacuta-Szumarska E, Będkowska GE, Szmitkowski M. Hematopoietic cytokines as tumor markers in gynecological malignancies. A multivariate analysis in epithelial ovarian cancer patients. Growth Factors 2012;30:357-66.

15. Cyżygier M, Ławicki S, Szmitkowski M. The plasma level of s-selectin, myeloperoxidase (MPO) and granulocyte-colony stimulating factor (G-CSF) in breast cancer patients after surgery. PrzeglLek 2009;66:433-6.

16. Vasiilades G, Kopianakis N, Vasiloglou M, Zografos G, Margaris H, Maselou K, et al. Role of the hematopoietic cytokines SCF, IL-3, GM-CSF and M-CSF in the diagnosis of pancreatic and ampullary cancer. Int J Biol Markers 2012;27:186-94.

17. Bahar B, AcedilAyc iota B, Çoğun U, Büyükberber S, Benekli M, Yıldız R. Granulocyte colony stimulating factor (G-CSF) and macrophage colony stimulating factor (M-CSF) as potential tumor markers in non small cell lung cancer diagnosis. Asian Pac J Cancer Prev 2010;11:709-12.

18. McDermott RS, Deneux L, Mosseri V, Vedrenne J, Clough K, Fourquet A, et al. Circulating macrophage colony stimulating factor as a marker of tumour progression. Eur Cytokine Netw 2002;13:121-7.

19. Kacinski BM. CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann Med 1995;27:79-85.

20. Scholl SM, Lidereau R, de la Rochefordière A, Le-Nir CC, Mosseri V, Nogues C, et al. Circulating levels of the macrophage-colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study. Breast Cancer Res Treat 1996;39:275-83.

21. Visse R and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-39.

22. Giannelli G, Enriquez R, Fransvea EA, Daniele A, Treutoli P, Schittulli F, et al. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int J Cancer 2004;109:782-5.

23. Jinga DC, Bildarud A, Cordrea I, Andreaua C, Dragomir C, Szelgi G, et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med 2006;10:499-510.

24. Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, et al. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 2008;122:2050-6.

25. Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, Gamero P. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a cross sectional and longitudinal evaluation. Br J Cancer 2006;95:506-14.

26. Ławicki S, Bedkowska GE, Szmitkowski M. VEGF, M-CSF and CA 15-3 as a new tumor marker panel in breast malignancies: a multivariate analysis with ROC curve. Growth Factors 2013;31:98-105.

27. Ławicki S, Szmitkowski M, Wojtkiewicz M. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients. ClinChimActa 2006;371:112-6.

28. Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res 1996;87:602-11.

29. McCarthy K, Maguire T, McGreal G, McDermott E, O’Higgins N, Duffy MJ. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999;84:44-8.